2Gloeckler Ries LA,Reichman ME,Lewis DR,et al.Cancer survival and incidence from the Surveillance,Epidemiology,and End Results (SEER) program[J].Oncologist,2003,8(6):541-552.
5[24]Paez JG, Janne PA, Lee Jc, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy.Science, 2004, 304:1497
6[25]Pao W, Miller V, Zakomski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers"and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA, 2004, 101 (36) : 13306
7[1]Wells A. The epidermal growth factor receptor (EGFR): A new target in cancer therapy. Signal, 2000, 1 (1) :4
9[3]Raben D, Helfrich BA, Chan D, et al. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol,2002, 29 (Suppl4) :37
10[4]Liu CY, Seen S. Gefitinib therapy for advanced non-small-cell lung cancer. Ann Pharmacother, 2003, 37 (11) :1644
